Trial
NCT00539617
Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of California, San Francisco
Collaborators
Genentech, Inc.
Condition
Esophageal Cancer
Intervention
Erlotinib
Why stopped
For slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-03-23